Brief: Aim Immunotech Announces Positive Data From Phase 2A Study Evaluating Ampligen
11/04/2022 12:28
April 11 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES POSITIVE DATA FROM PHASE 2A STUDY
EVALUATING AMPLIGEN® AS A COMPONENT OF A CHEMOKINE MODULATORY
(CKM) REGIMEN FOR THE TREATMENT OF COLORECTAL CANCER METASTATIC
TO THE LIVER
* AIM IMMUNOTECH INC- PRIMARY ENDPOINT OF STUDY WAS MET
* AIM IMMUNOTECH INC- DATA SUGGEST THAT CKM REGIMEN WITH
AMPLIGEN
MAY BE USEFUL TO ENHANCE EFFECTIVENESS OF IMMUNOTHERAPIES
Source text for Eikon: ID:nGNE1WTxwl
Further company coverage: AIM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential